White Paper

Shifting the Biomanufacturing Paradigm

Format: PDF file | Document type: White Paper | Promoted Content

This content is provided by Take the Right Path Upstream with MilliporeSigma, and any views and opinions expressed do not necessarily reflect those of www.biopharma-reporter.com

Shifting the Biomanufacturing Paradigm

The first commercial monoclonal antibody (mAb) was approved in 1986 and today, the global market is large and growing. Reports estimate the size of the market to be approximately $100 billion with expectations of it growing to more than $130 billion by 2023, a robust compound annual growth rate of more than 5.5%.

The demand for mAbs and other antibody-based biologics continues to be fueled by a number of factors including:

• A growing elderly population experiencing age-related conditions including cancer, cardiovascular and respiratory diseases
• The opportunity for significant breakthroughs in cancer, diabetes, liver and kidney diseases which continue to have high mortality rates
• The availability of biosimilars and novel modalities including bispecifics and antibody-drug conjugates

Related resources from Take the Right Path Upstream with MilliporeSigma

Show more

Supplier info centre